Comparison of abluminal biodegradable polymer biolimus‐eluting stents and durable polymer everolimus‐eluting stents in the treatment of coronary bifurcations

Abstract

BES use in the treatment of bifurcation lesions appears to be associated with good clinical outcomes, comparable to those seen with EES, at long-term follow-up. These results are hypothesis-generating and need to be validated with larger studies.

First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® — three-month results

“…In the BiOSS ® stent biodegradable polymer is applied, so the crucial matter is its stability and time of degradation. However, in other reports it was shown that the type of the polymer (biodegradable vs. durable) did not play a significant role in coronary bifurcation treatment [28].…”

First‐in‐Man Study of Dedicated Bifurcation Sirolimus‐eluting Stent: 12‐month Results of BiOSS LIM® Registry

“…In BiOSS® stent, the polymer is biodegradable, so crucial matter is its stability and time of degradation. However, in other papers, it was shown that the type of polymer (biodegradable vs durable) did not play a significant role in coronary bifurcation treatment …”

Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial

“…Currently, there are limited data regarding the clinical outcome of DES with biodegradable polymers used for stenting of bifurcation lesions . Our study clearly reinforces preliminary observations showing favorable intermediate‐term and long‐term outcomes, with a low rate of TLF and stent thrombosis following bifurcation stenting.…”